Treatment Action Group

Mission Statement

Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS.

TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information.

We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions.

TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.

How to Reach Treatment Action Group

Treatment Action Group
261 Fifth Avenue, Suite 2110
New York, NY 10016-7701

Phone: 212.253.7922
Fax: 212.253.7923
Email: tag@treatmentactiongroup.org
Web: www.treatmentactiongroup.org

Categories Covered:Tenofovir Disoproxil Fumarate (Viread), HIV Care and Services Outside the US, First-Line HIV Treatment, Switching or Stopping HIV Treatment, HIV Epidemiology, Adverse Events, Comorbidities, and HIV, HIV Treatments in Development, Meeting the Costs of HIV Care, HIV Policy and Advocacy, Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Abacavir/Lamivudine (Epzicom, Kivexa), HIV Prevention Methods, HIV Basic Science and Pathogenesis, Efavirenz (Sustiva, Stocrin), HIV Treatment Strategies, PrEP (HIV Pre-Exposure Prophylaxis), Pregnancy, Childbirth, and HIV, Didanosine (ddI, Videx), HIV Case Management and Social Work, U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), Enfuvirtide (T-20, Fuzeon), Tipranavir (Aptivus), Providing Quality HIV Care, HIV Education and Risk Management, FDA-Approved HIV Medications, HIV, Discrimination, and Law, Emtricitabine (FTC, Emtriva), HIV Testing, Atazanavir (Reyataz), Managing HIV Drug Resistance

Latest by Treatment Action Group

Keeping an Eye on Intellectual Property Issues in HIV Cure and Prevention Research

"As exemplified by the AZT protests, advocates have long pointed out the injustice of excessive, access-limiting profiteering on treatments developed with public support."

By Richard Jefferys for Treatment Action Group

Combining Broadly Neutralizing Antibodies Shows Promise

Results from the first human trials of a dual broadly neutralizing antibodies regimen appeared effective, safe, and well tolerated.

By Richard Jefferys for Treatment Action Group

Post-AIDS 2018 Updates on HIV Cure Research

In the aftermath of the 22nd International AIDS Conference (AIDS 2018), there has been some reflecting on the challenges facing the HIV cure research field.

By Richard Jefferys for Treatment Action Group

Studying HIV Persistence in Liver Macrophages

Invesitgators sought to determine whether human liver macrophages can sequester infectious HIV in people on antiretroviral therapy.

By Richard Jefferys for Treatment Action Group

The Usual Suspects: Common Challenges for End the Epidemic Planning and Implementation in Emerging Jurisdictions

Leaders and experts in End the Epidemic planning processes share their perspectives on some of the most common roadblocks.

By Jeremiah Johnson for Treatment Action Group

The Role of Vaccines and Cures in HIV Elimination

Even a moderately efficacious HIV vaccine could make a significant additional contribution to halting the virus. And for HIV-positive people, a true end to HIV lies not in an epidemiological calculus, but in a cure.

By Richard Jefferys for Treatment Action Group

Elite Controllers: Sex Differences and Factors Associated With Loss of Immune Control

The ability of elite controllers to maintain undetectable viral loads and relatively preserved CD4 T-cell counts in the absence of antiretroviral therapy has led them to be proposed as a model for a functional cure of HIV infection.

By Richard Jefferys for Treatment Action Group

Assessing Antiretroviral Therapy Interruptions in HIV Cure Research

During a clinical trial of the broadly neutralizing antibody VRC01, study results offered reassurance that treatment interruption had no long-term negative effects for participants -- but there are some possible safety concerns that the data does not...

By Richard Jefferys for Treatment Action Group

Recruiting Natural Killer Cells to Target HIV Persistence

There is growing interest in cells considered part of the innate immune system, particularly natural killer (NK) cells. A number of studies have been published that support the idea that NK cells can play an important role in controlling virus replic...

By Richard Jefferys for Treatment Action Group

New Data on Identifying and Targeting the Latent HIV Reservoir

Several recently presented and published studies offer potentially important new data relevant to efforts to identify cells containing latent HIV and target them for elimination.

By Richard Jefferys for Treatment Action Group